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Early days: genomics and human responses to infection
Minghsun Liu1, Stephen J Popper2, Kathleen H Rubins2 and
David A Relman1,2,3
DNA microarray-based gene transcript-profiling of the
responses of primates to infection has begun to yield new
insights into host–pathogen interactions; this approach,
however, remains plagued by challenges and complexities that
have yet to be adequately addressed. The rapidly changing
nature over time of acute infectious diseases in a host, and the
genetic diversity of microbial pathogens present unique
problems for the design and interpretation of functional-
genomic studies in this field. In addition, there are the more
common problems related to heterogeneity within clinical
samples, the complex, non-standardized confounding
variables associated with human subjects and the complexities
posed by the analysis and validation of highly parallel data.
Whereas various approaches have been developed to address
each of these issues, there are significant limitations that
remain to be overcome. The resolution of these problems
should lead to a better understanding of the dialogue between
the host and pathogen.
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Introduction
Since the last review in this journal of DNA microarray-
based transcriptome analysis for studying host responses
to infection [1], the adoption of this approach by research
groups around the world has continued unabated. This is
not surprising, given the rewards that have so far been
reaped from this genomic technology, especially in
understanding cancer and in the development of new
practical tools for classifying cancer patients on the basis
of disease outcome or predicted treatment-response. Yet,
as shown in Figure 1, the number of published papers on
DNA microarray-based host response profiling in the
setting of infectious diseases still lags significantly behind
the number of papers on the use of this approach in the
study of cancer. There are many probable reasons for this
discrepancy.
In this review, we focus on studies published from 2004 to
present that rely on the use of DNA microarrays to study
the host-response to pathogens using human clinical
samples or non-human primate models. The use of clin-
ical samples allows the study of host–pathogen interac-
tions in a clinically and physiologically relevant setting by
exploring the relationships between patterns of human
transcript abundance, human physiological parameters,
the natural history of the disease process, and pathogen
characteristics. The resulting complexity presents chal-
lenges beyond those posed by in vitro experimental
systems or small animal models. In this review, we
address some of the methodological issues raised by this
approach in this setting. An overview of some of the
factors to consider in designing DNA microarray-based
studies of infectious diseases is provided in Figure 2.
Readers interested in a broad overview of DNA micro-
array technology and microbial pathogenesis are referred
to two other recent reviews [2,3].
Where to ‘listen’: target tissue and cell type
In the study of naturally-occurring human disease the
restricted availability of tissues and cells of various types
often dictates the kinds of studies that are feasible. As
reflected in the current literature, twodifferent approaches
dominate in the selection of human clinical samples. The
first approach focuses on peripheral blood: peripheral
blood is a relatively accessible source of human cells
and RNA, and is a natural choice for analyzing host
transcript-based responses in systemic infection. This
approach has been used in the study of HIV infection
[4,5], sepsis [6], severe acute respiratory syndrome (SARS)
[7,8], malaria [9] and febrile illness as a result of upper
respiratory tract infections [10]. Most often, RNA is har-
vested from either peripheral blood mononuclear cells
(PBMC) or from whole blood; whole blood analysis
involves less manipulation of the specimen than do most
PBMC collection methods [11] and for this reason might
be particularly suitable for clinical field studies. However,
whole blood (which includes erythrocytes, granulocytes
and platelets in addition to the PBMC) is obviously amore
complex mixture of cell types, creating additional con-
foundingvariables, suchas the relative abundance levels of
these different cell types (see below). In addition, the large
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Figure 1
Number of published articles on gene expression profiling per year, by topic. The following search strategy was used in PubMed
(http:/www.pubmed.com) to identify articles focused on host-pathogen interactions: (‘‘Gene Expression Profiling’’ [MeSH] OR ‘‘Oligonucleotide
Array Sequence Analysis’’ [MESH]) AND (‘‘Parasitic Diseases’’ [MeSH] OR ‘‘Bacterial Infections and Mycoses’’ [MeSH] OR ‘‘Virus Diseases’’
[MeSH]). To identify similar articles discussing cancer-related gene expression patterns, the pathogen MeSH terms were replaced with
‘‘Neoplasms’’ [MeSH]. Abbreviation: MeSH, medical subject heading.
Figure 2
Factors to consider in microarray-based studies of the host response to infection. An overview of variables and points to consider when
designing and performing microarray experiments. Abbreviations: ANOVA, analysis of variance; CART, classification and regression tree;
MIAME, minimum information about a microarray experiment; PAM, predictive analysis of microarrays; qPCR, quantitative PCR; SAM,
significance analysis of microarrays; SOM, self organizing map; SVD, singular value decomposition.
www.sciencedirect.com Current Opinion in Microbiology 2006, 9:312–319
amount of haemoglobin gene transcripts present in RNA
preparations from whole blood samples might interfere
with microarray signals on some platforms (http://www.
affymetrix.com/support/technical/technotes/blood2_
technote.pdf), although we have not found any evidence
of this problemusing cDNAarrays in our laboratory (J Yen,
unpublished data).
The second approach has been to examine tissues or cells
that are prominently involved in infectious disease-asso-
ciated pathology: synovial fluid cells in septic knees [12],
explanted hearts in cardiomyopathy as a result of Chagas
disease [13], liver biopsies in hepatitis C-related fibrosis,
or in response to interferon therapy for this disease [14–
18], and gastric biopsies in Helicobacter pylori infection
[19,20]. In addition, several studies have examined HIV-
related dementia and encephalitis using brain tissues
obtained during autopsy [21–23]. The degree to which
host responses to infection are compartmentalized and
distinct between different compartments remains poorly
described. For example, the correlation between tran-
script abundance patterns in the peripheral blood and
those within local cells of various types at the site of a local
infection is unclear. It is not known how well peripheral
blood cells might discriminate between local infections
caused by different agents at different sites, or how well
they might reveal basic mechanisms of local immune
response. Clearly, the boundaries between local and
systemic compartments are not always distinct, because
there are molecular markers in the systemic circulation
that can be used as indicators of local infection. For
example, serum levels of creatine kinase-MB isoenzyme
and cardiac troponin I can be used to monitor myocardial
involvement in viral myocarditis; and serum hepatic
transaminase levels are used to measure the extent of
hepatocellular injury in viral hepatitis. Furthermore,
microbial disease agents might traffic through the per-
ipheral blood to a greater degree than previously sus-
pected (e.g. gastroenteritis-associated rotavirus).
Human clinical samples other than blood, and cells and
tissue from the primary site of infection associated pathol-
ogy might be useful for DNAmicroarray-based analysis of
infectious diseases. It remains to be seen how robust and
informative the RNA-based signatures are from saliva
[24] and other body fluids in this context; despite the
obvious challenges, the ease of access to some of these
sample types justifies further investigation. Various body
fluids have already been pursued as sources of protein-
based signatures of infectious disease.
The challenges of minimizing biases and
controlling confounding variables
Transcript abundance analysis of the host-response to
infection in model systems provides the opportunity to
control for, or eliminate, many of the variables present
during infection, including differences in environmental
factors, host genetic background, pathogen strain, infec-
tious dose, route and timing. Controlled studies of global
gene expression patterns in human subjects following
infection have not yet been published, although several
studies have reported on the consequences of adminis-
tering microbial components [25,26]. Instead, all of the
microarray-based studies cited above were observational
studies. As with any observational study, findings take the
form of associations between the measured variable (gene
transcript abundance) and other characteristics of the
process being studied (e.g. associated microbial agent,
survival and response to treatment); these findings are
subject to potential bias and confounding effects. An
unidentified or unspecified factor, or characteristic, might
lead to an incorrect interpretation — an unwarranted
inference of causality — or might limit the ability to infer
generalizations from the findings. This issue is prominent
in the typical microarray experiment, where thousands, or
tens of thousands of genes, reflecting diverse physiolo-
gical processes are examined all at once.
The potential for selection bias can be seen in one report
aimed at identifying genes whose expression levels might
be used as pretreatment predictors of responsiveness to
interferon therapy in patients with chronic hepatitis C
[17]. Patients infected with genotype 1 hepatitis C virus
have a significantly lower rate of response to interferon
therapy [27]. Not surprisingly, in these studies, patients
with genotype 1 infection were relatively over-repre-
sented in non-responder groups. Chen et al. [17]
addressed the possibility that the non-response transcrip-
tional profile was simply a genotype 1 profile, by deter-
mining that the same set of genes distinguished
responders and non-responders among those with geno-
type 1 infections. However, they did not evaluate their
findings in an independent set of samples, and because all
non-responders had genotype 1 virus, it is possible that
the identified genes only are associated with treatment
response in genotype 1 infection.
The collection of comprehensive data for a variety of
potentially-relevant clinical parameters provides an
important means of evaluating the role of potential con-
founders, and should be carefully considered during study
design. Studies in rats have shown that the expression of
some liver genes is influenced by fasting and circadian
rhythms [28]. However, none of the reports evaluating
liver gene expression in hepatitis C indicate whether diet
and time of day were recorded during sample collection,
or even considered in the data analysis [14–18,29]. The
issue is not unique to hepatic gene expression; transcript
abundance profiles in blood are also known to vary
according to gender, blood cell subset abundance, time
of day and age [11,30]. One approach, used in a study of
H. pylori-associated patterns of expression in gastric tissue
[19], is to match cases and controls on the basis of
potential confounding variables — in this study, samples
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were matched for age and gender. A second approach is to
eliminate from further analysis genes known to be sig-
nificantly associated with certain clinical parameters
[31]. Whereas both of these approaches if executed
carefully reduce the possibility of arriving at spurious
conclusions about the relationship between gene expres-
sion and an outcome of interest, they also limit the set of
possible subjects from which to draw samples for analysis,
and limit the possibility of discovering novel, interesting
associations between gene transcript abundance and the
matching variables. A third approach is to evaluate the
role of the clinical parameters during analysis. Chen et al.
[17] used multivariate analysis to evaluate the association
of specific genes with clinical parameters, and Griffiths
et al. [9] evaluated the strength of association of gene
expression patterns with each clinical parameter, and
identified gene subsets that were associated with each
variable. This latter study also demonstrated that certain
clinical parameters can help highlight for further study
specific aspects of the host transcript-based response to
infection, and help to elucidate biological mechanisms.
Sample size, pooling, replication, and
frequency
Determining the minimum and/or optimal number of
samples (the sample size) for microarray-based studies
remains an active research area (reviewed in [32]). None
of the studies reviewed for this paper made sample-size
determination explicit. At this time, sample size remains
largely determined by resource and sample availability.
Yet, it is disconcerting to find published microarray-based
in vivo studies that include only one sample for each
experimental group [33,34]. In addition to the obvious
benefit of achieving statistical significance, sample size
estimations facilitate collection of samples in sufficient
numbers so that a ‘tester set’ is available for cross-valida-
tion (see further discussion below).
Allison et al. [32] suggested that pooling of biological
samples can reduce variability but obscure the ability to
compare variables across individual samples. Pooling of
human clinical samples masks the clinical data from each
individual sample. The subsequent ability to correlate
gene expression patterns with specific clinical parameters
is then lost. Once a technical platform is proven reliable in
a given laboratory, biological replicates provide much
more information and value than technical replicates
(i.e. the same biological sample processed and hybridized
more than once).
Determining appropriate sampling frequency and time-
points is another important aspect of experimental
design. Unlike oncological or rheumatological diseases,
where the process evolves over months and years, the host
response during acute infectious disease is a much more
dynamic process, and can produce gene expression
changes over time scales ranging from minutes to hours.
Calvano et al. [25] showed that transcript responses to
one dose of intravenous endotoxin occur by the second
hour and resolve within 24 hours. In a previous report
from our lab, Rubins et al. [35] sampled blood from
monkeys with smallpox infection over multiple days and
found that an interferon-associated transcript abundance
response had begun by the first day or two after infection,
increased during the first four days and then plateaued
around day six. Other data from this study showed that
transcript abundance changes can precede the develop-
ment of clinical signs [35]. Taken together, these stu-
dies suggest that dense sampling over the time course of
infection, beginning prior to the appearance of clinical
signs, might be crucial for a complete picture of the gene
expression program during acute infectious disease.
Heterogeneity of cell populations in samples
Most human tissues and samples collected for microarray
analysis are a mixture of distinct cell types. A mixed cell
population, such as whole blood or PBMC, gives a com-
prehensive picture of gene expression during the sys-
temic host-response to infection, and reflects the overall
interactions within a complex system. However, the
complex dynamics of a heterogeneous sample poses
two different challenges for in vivo experiments. An
important gene expression pattern might be undetectable
amidst a ‘noisy’ environment, particularly a pattern gen-
erated by a rare cell population. In addition, increases or
decreases in the relative abundance of a cell type alters
the overall proportion of unique transcripts from that cell
type in the total pool of RNA from a given sample. The
resulting gene transcript data might simply be a reflection
of the sum of unique, constitutive transcript profiles from
each cell type, rather than an actual increase or decrease
in transcript levels within a given cell type in response to
the infection or stimulus.
Two studies have examined the different contributions of
individual cell types in a complex in vivo mixed popula-
tion. Mueller et al. [36] used laser micro-dissection to
harvest the three major epithelial cell types from murine
stomach tissue and showed that a H. pylori-specific tran-
scriptional profile is induced only in the mucus-producing
pit cells. McLaren et al. [34] compared gene expression
differences between antigen-stimulated PBMC and
CD4+ and CD8+ T-lymphocyte subpopulations. Their
limited analysis suggested that the transcript patterns of
lymphocyte subpopulations are distinct and differ from
the PBMC population as a whole.
Some in vitro experiments have explored gene transcript
patterns of specific cell subpopulations, sometimes in
response to specific stimuli [30,37] (Waddell et al., manu-
script in preparation). These ‘reference studies’ have
produced gene lists that can potentially be used as sig-
natures for determining the contributions of different cell
subsets to the profile of a mixed population without
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having to separate each subset ex vivo. Several in vivo
studies have recognized the contribution of cell popula-
tion dynamics to gene expression patterns and have
performed correlation analysis to identify cell subset
abundance effects [9,11,35]. However, the utility of
these secondary data analysis techniques, for example,
correlation and signature gene lists, for identifying infec-
tion responses in a complex cell mixture remains to be
determined.
Whether cell sorting and separation is necessary in a study
will depend upon the specific experimental aims. For
studies with a focus on diagnosis, prediction or classifica-
tion, it might be acceptable to include patterns reflective
of both fluctuating cell populations and gene regulation.
However, for studies that are designed to elucidate
pathogenesis or mechanism, the difficulties in sorting
out contributions from each of these factors could prove
too problematic. At a minimum, studies that sample
complex tissues and mixtures of cells should collect data
on the abundance of various cell types during the time-
frame of the disease process. Reduction of sample com-
plexity through purification of individual cell populations
might be a necessary and important approach in the
future.
Reporting and availability of microarray data
One of the most powerful and as yet, under-utilized
approaches to microarray data analysis is to combine
primary gene transcript abundance data from different
studies in a ‘meta-analysis’. Jenner and Young [2]
employed this approach with a re-analysis of data from
32 studies of host–pathogen interactions. This study
demonstrated both a common transcriptional response
to pathogens across cell types and studies, as well as
specific responses involving Toll-like receptors and sub-
sets of pathogens. However, the usefulness of this
approach is limited by the quality and availability of
the underlying data. Many transcript profiling papers
simply list ‘‘induced’’ or ‘‘repressed’’ genes, without
making available the underlying raw data, or even the
values of the clustered and filtered data upon which the
lists were based. This type of data reporting structure
does not allow for rigorous peer-review of the data, and
prohibits future types of combinatorial analysis. In addi-
tion, many investigators simply create rank lists of fold
changes in transcript abundance as proof for differential
expression and proceed to make inferential statements
and conclusions based on the highly ranked genes. This
approach assumes that the variance in transcript levels for
every gene is the same — this is not true in most
experiments, leading to unfounded conclusions [32].
In 2001, a set of standards was proposed for the review
and publication of microarray data [38] (http://www.mged.
org/Workgroups/MIAME/miame.html). Submission of
microarray data to a public database such as ArrayExpress
[39], Gene Expression Omnibus (GEO) [40], or the
Center for Information Biology Gene Expression Data-
base (CIBEX) [41], should be a basic requirement by all
journals for publication of manuscripts that present these
data, in the same way that submission of gene or protein
sequence data to public databases is currently required
for publication. The latter requirement has proved
invaluable for researchers worldwide. The wealth of
information generated with microarray experiments
can only be fully exploited if the data aremade accessible
to the public.
Validation
‘Validation’ is a term that has been used loosely in the
gene expression literature. Generally, validation of results
from microarray profiling of host response refers to the
corroboration of changes in gene transcript levels using an
independent experimental method, such as quantitative
real-time PCR (RT-PCR). There is no current consensus
on the suitability or need for RT-PCR as an appropriate
and/or indicated method for confirmation of microarray
data [32]. Need might be, in part, based on the impor-
tance of obtaining precise quantitative data for specific
transcripts in a particular study. At the same time, when a
group of co-varying transcripts is found, all of which are
known to be associated with the same biological system or
signaling pathway, this is strong evidence that this system
or pathway is affected by the process under study; inde-
pendent measurements of specific transcripts might not
be necessary. Some recent microarray designs incorporate
extensive internal controls, further reducing the need for
RT-PCR: one example is the HEEBO (human exonic
evidence-based oligonucleotide) and MEEBO (mouse
exonic evidence-based oligonucleotide) arrays designed
by Alizadeh et al. (http://alizadehlab.stanford.edu). As an
alternative, measurement of predicted protein products
might be more appropriate in some settings [19]. Rubins
et al. [35] pursued leads generated by microarray experi-
ments with measurements of interferon protein — fol-
lowing up on the increased abundance of known
interferon-regulated gene transcripts, and with detection
of apoptotic T-cells by TUNEL (terminal deoxynucleo-
tidyl transferase biotin–dUTP nick end labelling) assays
— following up on the decreased abundance of certain
T-lymphocyte-associated transcripts. Obviously, valida-
tion of biological leads using in vitro models of host–
pathogen interaction remains far easier than validation of
such findings in humans [42,43].
One of the major advantages of an agnostic method like
genome-wide transcript profiling is that it can highlight
potentially important genes without being biased or lim-
ited by prior assumptions about an experimental system.
Researchers tend to ‘‘only look where the streetlight is’’,
in focusing on genes with familiar names. Pre-existing
reagents and tools encourage this behavior, but the
increasing availability of comprehensive, genome-wide
316 Techniques
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gene ‘knock-down’ tools [44] should significantly
improve the ability to study unknown genes identified
in microarray experiments.
Appropriate cross-validation should be performed in stu-
dies that generate classifier or predictor sets of genes
based on microarray data; Tibshirani et al. [45] provides a
brief discussion on the challenges of classification in this
setting. In several studies, sets of differentially expressed
genes were used to assign samples or cases to clinical
categories [6,9,10,14,17]. However, in at least one study,
no effort was made to deal with generalization error [6],
thus severely weakening the strength of the findings.
Conclusion: forming the big picture
The promise that genomics would improve our under-
standing of host–pathogen interactions has yet to be fully
realized. Yet there are clear indications that progress is
accelerating and new insights are accruing. The popular-
ity of microarray-based technologies for examining these
interactions will continue to expand as costs diminish,
standards are propagated and techniques improve. The
degree to which the associated explosion in the quantity
of available data is accompanied by comparable gains in
biological insight will depend on thoughtful study design,
careful data analysis, appropriate follow-up experiments,
and public availability of well-annotated, raw, standar-
dized microarray data.
Currently, it is also clear that we are not extracting all
available higher-order information from these data. Sev-
eral gene class annotation tools have been developed to
identify and organize biological themes among differen-
tially expressed genes [46,47]. Bioinformatics tools, such
as those employed by Calvano et al. [25] and Koller’s
group [48,49], will further enhance the interpretation of
microarray data. In particular, Koller et al. have developed
creative computational modeling approaches for dedu-
cing biological processes and regulatory networks, based
on integration of multiple kinds of highly-parallel gen-
ome-wide data, such as primary sequence, gene transcript
abundance and protein–DNA association data [48].
From the genomic perspective, host–pathogen interac-
tions involve the interplay of two (or more) distinct
genomes. A more comprehensive study of these interac-
tions will entail simultaneous monitoring of all of the
associated genes and gene products [50,51]. We believe
that one of the most exciting prospects for this field lies in
the integration of genome-wide data from multiple
sources. Large-scale random shotgun sequencing efforts
using samples from complex microbial communities pro-
vide an opportunity to discover and monitor the expres-
sion of genes directly from samples of these communities,
whether they are host-associated or environment-asso-
ciated. Community-wide patterns of gene transcript
abundance and their variation with respect to time, space
and perturbation will reveal fundamentally important
aspects of microbial community ecology and physiology,
and provide potentially useful diagnostic and prognostic
information about the hosts in which communities play
critical roles in health and disease. As we construct a high
resolution and dynamic picture of the conversation
between humans and microbes, we will not only enhance
our understanding about fundamental aspects of human
biology, but improve the clinical management of infec-
tious diseases.
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